

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **“TOFACITINIB CITRATE TABLETS” OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Tofacitinib Citrate Tablets (5mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.\* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Tofacitinib citrate tablet is the first small molecule targeted inhibitor of Janus kinase (JAK) for the treatment of rheumatoid arthritis. It is indicated for adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response or intolerance to methotrexate. It can be used in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

The approval of the Product further enriches the Group’s product portfolio and enhances the Group’s development in the field of autoimmune diseases.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 25 June 2021

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

*\* For identification purposes only*